Melanoma Journal Articles for January 2017

Computation 20175(1), 4; doi:10.3390/computation5010004

An SVM Framework for Malignant Melanoma Detection Based on Optimized HOG Features

Samy Bakheet


J Immunother. 2016 Jan; 39(1): 15–26.

doi:  10.1097/CJI.0000000000000103

Identification of melanoma-reactive CD4+ T cell subsets from Human Melanoma Draining Lymph Nodes

Mei Zhang,1,2,3 Hallie Graor,3 Lu Yan,1 and Julian Kim


Which symptoms are linked to a delayed presentation among melanoma patients? A retrospective study

Sally Jane O’Shea, Zoe Rogers, Fiona Warburton, Amanda J. Ramirez, Julia A. Newton-Bishop and Lindsay J. L. Forbes

BMC Cancer201717:5

DOI: 10.1186/s12885-016-2978-6

Received: 30 November 2015

Accepted: 29 November 2016

Published: 3 January 2017


Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor

Julia Escandon, Stephanie Peacock, Asaad Trabolsi, David B. Thomas, Ayman Layka and Jose Lutzky

Journal for ImmunoTherapy of Cancer20175:3

DOI: 10.1186/s40425-016-0205-2

Received: 27 June 2016

Accepted: 15 December 2016

Published: 17 January 2017


BioRxiv

Recurrent promoter mutations in melanoma are defined by an extended context-specific mutational signature

Johan Fredriksson, Kerryn Eliot, Stefan Filges, Anders Stahlberg, Erik Larsson

doi: https://doi.org/10.1101/069351


Replication Study: Melanoma genome sequencing reveals frequent PREX2 mutations

Stephen K Horrigan, Pascal Courville, Darryl Sampey, Faren Zhou, Steve Cai,

  • Reproducibility Project: Cancer Biology

Noble Life Sciences, United States; BioFactura, United States; TACGen, United States

DOI: http://dx.doi.org/10.7554/eLife.21634

Published January 19, 2017

Cite as eLife 2017;6:e21634


Melanoma Cell Adhesion and Migration Is Modulated by the Uronyl 2-O Sulfotransferase

Katerina Nikolovska, Dorothe Spillmann, Jörg Haier, Andrea Ladányi, Christian Stock, Daniela G. Seidler

 

 


Underexpression of Specific Interferon Genes Is Associated with Poor Prognosis of Melanoma

  • Aamir Zainulabadeen,
  • Philip Yao,
  • Habil Zare

 

 


Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells

Souvik Banerjee, Derek D. Norman, Sue Chin Lee, Abby L Parrill, Truc Chi T. Pham, Daniel L. Baker, Gabor G. Tigyi, and Duane D Miller

  1. Med. Chem., Just Accepted Manuscript

DOI: 10.1021/acs.jmedchem.6b01270

Publication Date (Web): January 23, 2017

Copyright © 2017 American Chemical Society


Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.

Liechtenstein T., Perez-Janices N., Blanco-Luquin I., Goyvaerts C., Schwarze J., Dufait I., Lanna A., Ridder M., Guerrero-Setas D., Breckpot K., Escors D.

 

Oncoimmunology

10.4161/21624011.2014.945378


BOOK

Chapter

Melanoma Development

pp 39-61

Date: 26 January 2017

Melanoma Epidemiology

Marianne Berwick


Ipilimumab Adjuvant Therapy in Melanoma

G Ianiro et al. N Engl J Med 376 (4), 398. 2017 Jan 26.

PubMed: 28125193


Epigenomes 20171(1), 3; doi:10.3390/epigenomes1010003

New Frontiers in Melanoma Epigenetics—The More We Know, the More We Don’t Know

Marzena Nguyen  and Paula Dobosz 

Received: 31 December 2016 / Accepted: 25 January 2017 / Published: 30 January 2017


Uveal melanoma: epidemiology, etiology, and treatment of primary disease

Authors Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD

Received 30 August 2016

Accepted for publication 22 November 2016

Published 31 January 2017 Volume 2017:11 Pages 279—289

DOI https://doi.org/10.2147/OPTH.S89591


 

 

Menu